0.94
+0.0151(+1.63%)
Currency In USD
| Previous Close | 0.92 |
| Open | 0.93 |
| Day High | 0.95 |
| Day Low | 0.92 |
| 52-Week High | 1.8 |
| 52-Week Low | 0.69 |
| Volume | 123,535 |
| Average Volume | 298,903 |
| Market Cap | 30.57M |
| PE | -1.03 |
| EPS | -0.91 |
| Moving Average 50 Days | 0.98 |
| Moving Average 200 Days | 1.16 |
| Change | 0.02 |
If you invested $1000 in Femasys Inc. (FEMY) since IPO date, it would be worth $78.32 as of July 14, 2025 at a share price of $0.94. Whereas If you bought $1000 worth of Femasys Inc. (FEMY) shares 3 years ago, it would be worth $467.61 as of July 14, 2025 at a share price of $0.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
GlobeNewswire Inc.
Jul 01, 2025 1:00 PM GMT
-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet nee
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
GlobeNewswire Inc.
Jun 25, 2025 1:00 PM GMT
--European CE mark approval of the entire FemBloc® system marks pivotal achievement in expanding safe, accessible and non-surgical permanent contraceptive options for women--ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
GlobeNewswire Inc.
Jun 17, 2025 1:00 PM GMT
--New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed®, and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (Nasdaq: FEMY), a leading biomedical inno